← All agents | ← Research tracker
Metformin
Also known as: Metformin
PubChem entry
Evidence Summary
Evidence Level: Moderate
Mechanism: Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Metabolic / Mitochondrial
Safety: GI side effects (diarrhea, nausea) common initially. Risk of B12 deficiency long-term; lactic acidosis rare (avoid in severe renal/hepatic disease, contrast).
Dosing: 500–2000 mg/day (extended release often better tolerated); prevention trials used during acute infection ~14 days; treatment studies 8–12+ weeks.
Prevention signal strong; treatment data mixed/preliminary. 500-2000mg. GI effects, B12. Reasonable metabolic adjunct in overweight PASC patients.
Related Conditions
Gulf War Illness (no page yet) · Long COVID (no page yet) · ME/CFS (no page yet)
Clinical Trials
3 trial(s) registered
NCT04510194: COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) PHASE3 COMPLETED
NCT06128967: A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial PHASE3 COMPLETED
NCT06147050: Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents PHASE3 UNKNOWN
Key Studies / References